Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma

Clinical features and the molecular biomarkers of olfactory neuroblastoma

(2018) Xiaolin Peng et al.   PATHOLOGY RESEARCH AND PRACTICE

Hypopharyngeal carcinoma: Do you know your guidelines?

(2018) Daniel I. Kwon et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

DT-13 Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells Through Blocking PI3K/Akt Pathway

(2018) Zhengming Wang et al.   Frontiers in Pharmacology

The PI3K/AKT Pathway as a Target for Cancer Treatment

(2016) Ingrid A. Mayer et al.   Annual Review of Medicine

Treatment trends and survival effects of chemotherapy for hypopharyngeal cancer: Analysis of the National Cancer Data Base

(2016) Phoebe Kuo et al.   CANCER

In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells

(2016) Qianxiang Zhou et al.   International Journal of Biological Sciences

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma

(2016) Thomas Powles et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

(2016) Cristian Massacesi et al.   OncoTargets and Therapy

Stellettin B Induces G1 Arrest, Apoptosis and Autophagy in Human Non-small Cell Lung Cancer A549 Cells via Blocking PI3K/Akt/mTOR Pathway

(2016) Ran Wang et al.   Scientific Reports

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

(2016) Linda S. Steelman et al.   Aging-US

Predictive and Prognostic Biomarkers for Patients Treated with Anti-EGFR Agents in Lung Cancer: A Systemic Review and Meta-Analysis

(2015) Ying Wang et al.   Asian Pacific Journal of Cancer Prevention

Dual inhibition of allosteric mitogen-activated protein kinase (MEK) and phosphatidylinositol 3-kinase (PI3K) oncogenic targets with a bifunctional inhibitor

(2015) Marcian E. Van Dort et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells

(2015) Dan Zi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations

(2015) Thomas F Eleveld et al.   NATURE GENETICS

Development of an Immunohistochemical Protein Quantification System in Conjunction with Tissue Microarray Technology for Identifying Predictive Biomarkers for Phosphatidylinositol 3-Kinase Inhibitors

(2015) Sho Isoyama et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Survival trends in Hypopharyngeal cancer: A population-based review

(2015) J. Robert Newman et al.   LARYNGOSCOPE

Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration

(2014) Sujoy Dutta et al.   Molecular Oncology

Characterization of HPV and host genome interactions in primary head and neck cancers

(2014) M. Parfenov et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo

(2013) J. Renshaw et al.   CLINICAL CANCER RESEARCH

Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin β1 expression and the ERK1/2 signaling pathway

(2013) Heyong Wang et al.   TOXICOLOGY

Targeting PI3K in Cancer: Any Good News?

(2013) Miriam Martini et al.   Frontiers in Oncology

Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance

(2012) Edita Aksamitiene et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

(2012) Antonella De Luca et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer

(2012) T. M. Williams et al.   MOLECULAR CANCER THERAPEUTICS

Targeted therapy in head and neck cancer

(2012) S. K. Kundu et al.   TUMOR BIOLOGY

Activation and Function of the MAPKs and Their Substrates, the MAPK-Activated Protein Kinases

(2011) M. Cargnello et al.   MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS

A Perspective on Cancer Cell Metastasis

(2011) C. L. Chaffer et al.   SCIENCE

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

(2011) Michelle C. Mendoza et al.   TRENDS IN BIOCHEMICAL SCIENCES

New advances in targeted therapies for squamous cell carcinoma of the head and neck

(2010) Jean-Pascal Machiels et al.   ANTI-CANCER DRUGS

Correlating Phosphatidylinositol 3-Kinase Inhibitor Efficacy with Signaling Pathway Status:In silicoand Biological Evaluations

(2010) Shingo Dan et al.   CANCER RESEARCH

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy

(2008) J A McCubrey et al.   LEUKEMIA

Down-regulation of PKCζ expression inhibits chemotaxis signal transduction in human lung cancer cells

(2008) Ying Liu et al.   LUNG CANCER